How Real-World Evidence Is Rewriting the Rules of Drug Approval

The randomized controlled trial is still the gold standard for proving a drug works. But regulators are no longer treating it as the only standard.

Between late 2025 and early 2026, the FDA rolled out two major guidance updates that reshaped how Real-world evidence (RWE) is used in regulatory decisions. The message was clear: lower the barriers around real-world data access, but raise the bar on data quality, provenance, and methodology.

In December 2025, the FDA opened the door to de-identified, aggregate-level data for certain device submissions unlocking national cancer registries, hospital EHR systems, and insurance claims databases as legitimate evidence sources. Then in March 2026, the FDA adopted ICH M14, a harmonized standard (built with the EMA and Japan's PMDA) that governs how sponsors must design and report non-interventional safety studies. Translation: you can't just export EHR data and call it evidence anymore. It has to be built to standard.

The EMA moved in lockstep. Its finalized EMA data quality framework real-world data chapter, adopted by the CHMP, gives regulators, sponsors, CROs, and data networks like DARWIN EU a shared rulebook for assessing RWD quality across the EU.

Why does this matter commercially? The global real-world data market is projected to roughly double by 2030, driven by regulatory acceptance, AI-driven analytics, and personalized medicine. And it's showing up in outcomes already roughly a quarter of FDA labeling expansions between 2022–2024 leaned on some form of real-world evidence.

But regulatory acceptance doesn't automatically create regulatory-grade evidence. That gap between raw data and submission-ready evidence is an infrastructure problem. It takes integrated pipelines that can harmonize EHR, claims, registry, genomic, and wearable data at scale, with privacy-by-design built in from day one.

That's the exact problem ClairLabs' RWD & RWE services are built to solve turning fragmented real-world data into audit-ready evidence packages for FDA, EMA, and HTA submissions, in weeks rather than quarters.

For regulatory strategists, the question in 2026 isn't whether to invest in RWE. It's whether your data infrastructure can meet the bar regulators have already raised.